merck oral glp-1 New Competition in the Track: The Patent Layout and Clinical Journey of Hansoh's HS-10535 Merck moves into obesity with

A 2025 radiographic study found an average 7% reduction in midfacial volume for every 10 kilograms of total weight lost, with most of the change occurring in superficial facial fat pads

Most semaglutide patients hit their goal weight after a year of treatment

Injecting through clothing: Never inject through clothing, even thin fabric

To explore insured impacts further, and how this may translate to your policyholders, reach out to your local RGA representative.

Additionally, we found that high glucose (20 mM)-induced insulin secretion, inhibited by 1 M pasireotide, was higher than insulin secretion in the low-glucose (2 mM) state

Being prepared helps